Last reviewed · How we verify

A-101 Solution — Competitive Intelligence Brief

A-101 Solution (A-101 Solution) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical cytolytic agent. Area: Dermatology.

phase 3 Topical cytolytic agent Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

A-101 Solution (A-101 Solution) — Aclaris Therapeutics, Inc.. A-101 is a topical solution that induces controlled necrosis of skin lesions through a proprietary mechanism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
A-101 Solution TARGET A-101 Solution Aclaris Therapeutics, Inc. phase 3 Topical cytolytic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical cytolytic agent class)

  1. Aclaris Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). A-101 Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/a-101-solution. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: